RNAi developer Protiva raises $3.3M
Protiva, a Vancouver, B.C.-based developer of drugs based on the new technology of RNA interference, raised $3.3 million in debenture financing. Investors included GrowthWorks Capital, BDC Capital, the Canadian Medical Discoveries Fund and Kinetic Capital.
Protiva is currently embroiled in litigation against two other biotechs, including Sirna Therapeutics, another RNAi company acquired by Merck last December, and Tekmira Pharmaceuticals.
Next Story: SpectraSensors raises $14M for natural gas analysis
Previous Story: 100 invites to VeohTV
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.